

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| SUBMISSION TYPE: | NEW ASSIGNMENT | | | | | | | | | | | | | | | | |
|--|--------------------|---------------|--------------------|---------------------|-----------------|----------------------|------------|----------------|-------------|-------------------|------------|-------------------|------------|------------------|------------|----------------|------------|
| NATURE OF CONVEYANCE: | ASSIGNMENT | | | | | | | | | | | | | | | | |
| CONVEYING PARTY DATA | | | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Giorgio Caravatti</td> <td>01/23/2013</td> </tr> <tr> <td>Robin Alec Fairhurst</td> <td>01/24/2013</td> </tr> <tr> <td>Pascal Furet</td> <td>01/28/2013</td> </tr> <tr> <td>Frederic Stauffer</td> <td>01/30/2013</td> </tr> <tr> <td>Frank Hans Seiler</td> <td>02/01/2013</td> </tr> <tr> <td>Heinrich Rueeger</td> <td>01/30/2013</td> </tr> <tr> <td>Clive McCarthy</td> <td>01/21/2013</td> </tr> </tbody> </table> | | Name | Execution Date | Giorgio Caravatti | 01/23/2013 | Robin Alec Fairhurst | 01/24/2013 | Pascal Furet | 01/28/2013 | Frederic Stauffer | 01/30/2013 | Frank Hans Seiler | 02/01/2013 | Heinrich Rueeger | 01/30/2013 | Clive McCarthy | 01/21/2013 |
| Name | Execution Date | | | | | | | | | | | | | | | | |
| Giorgio Caravatti | 01/23/2013 | | | | | | | | | | | | | | | | |
| Robin Alec Fairhurst | 01/24/2013 | | | | | | | | | | | | | | | | |
| Pascal Furet | 01/28/2013 | | | | | | | | | | | | | | | | |
| Frederic Stauffer | 01/30/2013 | | | | | | | | | | | | | | | | |
| Frank Hans Seiler | 02/01/2013 | | | | | | | | | | | | | | | | |
| Heinrich Rueeger | 01/30/2013 | | | | | | | | | | | | | | | | |
| Clive McCarthy | 01/21/2013 | | | | | | | | | | | | | | | | |
| RECEIVING PARTY DATA | | | | | | | | | | | | | | | | | |
| <table border="1"> <tr> <td>Name:</td> <td>Novartis Pharma AG</td> </tr> <tr> <td>Street Address:</td> <td>Lichtstrasse 35</td> </tr> <tr> <td>City:</td> <td>Basel</td> </tr> <tr> <td>State/Country:</td> <td>SWITZERLAND</td> </tr> <tr> <td>Postal Code:</td> <td>4056</td> </tr> </table> | | Name: | Novartis Pharma AG | Street Address: | Lichtstrasse 35 | City: | Basel | State/Country: | SWITZERLAND | Postal Code: | 4056 | | | | | | |
| Name: | Novartis Pharma AG | | | | | | | | | | | | | | | | |
| Street Address: | Lichtstrasse 35 | | | | | | | | | | | | | | | | |
| City: | Basel | | | | | | | | | | | | | | | | |
| State/Country: | SWITZERLAND | | | | | | | | | | | | | | | | |
| Postal Code: | 4056 | | | | | | | | | | | | | | | | |
| PROPERTY NUMBERS Total: 1 | | | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13773947</td> </tr> </tbody> </table> | | Property Type | Number | Application Number: | 13773947 | | | | | | | | | | | | |
| Property Type | Number | | | | | | | | | | | | | | | | |
| Application Number: | 13773947 | | | | | | | | | | | | | | | | |
| CORRESPONDENCE DATA | | | | | | | | | | | | | | | | | |
| Fax Number: <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> Phone: 617-871-4027 Email: pip_inbox.phchbs@novartis.com Correspondent Name: Nicholas J. Landry Address Line 1: 220 Massachusetts Ave. Address Line 4: Cambridge, MASSACHUSETTS 02139 | | | | | | | | | | | | | | | | | |
| ATTORNEY DOCKET NUMBER: | PAT054969-US-NP | | | | | | | | | | | | | | | | |

NAME OF SUBMITTER:

Nicholas J. Landry

Total Attachments: 12

source=PAT054969-US-NP_assignment inventors to NPHAG#page1.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page2.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page3.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page4.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page5.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page6.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page7.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page8.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page9.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page10.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page11.tif
source=PAT054969-US-NP_assignment inventors to NPHAG#page12.tif

Patent Family Number PAT054969

ASSIGNMENT

This Assignment Agreement is entered into by and between

| | | |
|----------------------|---------------------------|--|
| Giorgio CARAVATTI | citizen of Switzerland | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Robin Alec FAIRHURST | citizen of United Kingdom | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Pascal FURET | citizen of France | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Frédéric STAUFFER | citizen of Switzerland | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Frank Hans SEILER | citizen of Germany | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Clive MCCARTHY | citizen of United Kingdom | Evotec 114 Milton Park Abingdon, Oxfordshire OX14 4SA GB |
| Heinrich RUEEGER | citizen of Switzerland | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |

(hereinafter "Inventor(s)"), and **NOVARTIS PHARMA AG**, Lichtstrasse 35, 4056 Basel, Switzerland, a company organized under the laws of Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS PHARMA AG is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS PHARMA AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF
[Patent Application PAT054969-US-PSP02]

and filed in the _____ Office on _____, 20____ and accorded Application Number _____ and/or filed as a PCT International Application on _____, 20____ and accorded International Patent Application Number PCT/_____; and/or filed in the United States Patent and Trademark Office on February 24, 2012 and accorded Application Number 61/602,954; and/or filed in the United States Patent and Trademark Office on December 13, 2012 and accorded Application Number 61/736,707;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property

office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 23 day of January, 2013.

BY Giorgio Caravatti L.S.
Giorgio Caravatti

Executed this 24 day of January, 2013

BY Robin Alec Fairhurst L.S.
Robin Alec Fairhurst

Executed this 28 day of January, 2013

BY Pascal Furet L.S.
Pascal Furet

Executed this 30 day of January, 2013.

BY Frederic Stauffer L.S.
Frederic Stauffer

Executed this 01 day of February, 2013.

BY Frank Hans Seiler L.S.
Frank Hans Seiler

Executed this _____ day of _____, 20____.

BY _____ L.S.
Clive McCarthy

Executed this 30 day of January, 2013.

BY Heinrich Rueeger L.S.
Heinrich Rueeger

NOVARTIS PHARMA AG

Executed this 5th day of Feb., 2013.

BY Sabine Zeller L.S.
Name: Sabine Zeller
Title: Authorized signatory

BY Reto Halbeisen L.S.
Name: Reto Halbeisen
Title: Authorized signatory

ATTESTATION

I, the undersigned, Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signatures attached heretofore are the genuine signatures of **Mr. Giorgio Caravatti**, citizen of Biasca, Switzerland, residing in Bottmingen, Switzerland; of **Robin Alec Fairhurst**, British citizen, born on September 16 (sixteen), 1965 (nineteen hundred sixty five), with business address Klybeck, Postfach, 4002 Basel; of **Mr. Pascal Furet**, French citizen, residing in Thann, France; of **Mr. Frédéric Stauffer**, citizen of Homberg BE, residing in Hémingue, France; of **Mr. Frank Hans Seiler**, German citizen, residing in Freiburg, Germany; and of **Mr. Heinrich Rüeger**, citizen of Elaus ZH, Switzerland, residing in Flüh SO, Switzerland.

I further certify that the signatures attached heretofore are the genuine signatures of **Ms. Sabine Zeller**, citizen of Ormalingen, Switzerland, residing in Gelterkinden, Switzerland; and of **Mr. Reto Halbeisen**, citizen of Wahlen/BL, Switzerland, residing in Basel, Switzerland, both acting for **Novartis Pharma AG**, in Basel, Switzerland, both as proxy holders and both with joint signature.

The authenticity of the signatures was established by means of comparison.

BASEL, Switzerland, this 11th (eleventh) day of February 2013 (two thousand and thirteen)

M. Staehelin, Notar

Dr. M. Staehelin
Notar

Leg. Prot. Nr. 344/2013

Patent Family Number PAT054969

ASSIGNMENT

This Assignment Agreement is entered into by and between

| | | |
|----------------------|---------------------------|--|
| Giorgio CARAVATTI | citizen of Switzerland | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Robin Alec FAIRHURST | citizen of United Kingdom | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Pascal FURET | citizen of France | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Frédéric STAUFFER | citizen of Switzerland | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Frank Hans SEILER | citizen of Germany | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |
| Clive MCCARTHY | citizen of United Kingdom | Evotec 114 Milton Park Abingdon, Oxfordshire OX14 4SA GB |
| Heinrich RUEEGER | citizen of Switzerland | Novartis Pharma AG Werk Klybeck Postfach 4002 Basel CH |

(hereinafter "Inventor(s)"), and **NOVARTIS PHARMA AG**, Lichtstrasse 35, 4056 Basel, Switzerland, a company organized under the laws of Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS PHARMA AG is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS PHARMA AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF
[Patent Application PAT054969-US-PSP02]

and filed in the _____ Office on _____, 20____ and accorded Application Number _____ and/or filed as a PCT International Application on _____, 20____ and accorded International Patent Application Number PCT/_____; and/or filed in the United States Patent and Trademark Office on February 24, 2012 and accorded Application Number 61/602,954; and/or filed in the United States Patent and Trademark Office on December 13, 2012 and accorded Application Number 61/736,707;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property

office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____, 20____.

BY _____ L.S.
Giorgio Caravatti

Executed this _____ day of _____, 20____.

BY _____ L.S.
Robin Alec Fairhurst

Executed this _____ day of _____, 20____.

BY _____ L.S.
Pascal Furet


Executed this _____ day of _____, 20____.

BY _____ L.S.
Frederic Stauffer

Executed this _____ day of _____, 20____.

BY _____ L.S.
Frank Hans Seiler

Executed this _____ day of _____, 20____.


BY  L.S.
Clive McCarthy


Executed this 21st day of JANUARY, 2013.

BY _____ L.S.
Heinrich Rueeger

NOVARTIS PHARMA AG

Executed this 3rd day of Feb, 2013

BY  L.S.
Name: Sabine Zeller
Title: Authorized signatory

BY  L.S.
Name: Reto Halbeisen
Title: Authorized signatory

ATTESTATION

I, the undersigned, Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signature attached heretofore is the genuine signature of **Mr. Clive McCarthy**, British citizen, residing in Froidefontaine, France.

I further certify that the signatures attached heretofore are the genuine signatures of **Ms. Sabine Zeller**, citizen of Ormalingen, Switzerland, residing in Gelterkinden, Switzerland; and of **Mr. Reto Halbeisen**, citizen of Wahlen/BL, Switzerland, residing in Basel, Switzerland, both acting for **Novartis Pharma AG**, in Basel, Switzerland, both as proxy holders and both with joint signature.

The authenticity of the signatures was established by means of comparison.

BASEL, Switzerland, this 11th (eleventh) day of February 2013 (two thousand and thirteen)

M. Staehelin, Notar

Dr. M. Staehelin
Notar

Leg. Prot. Nr. 312 /2013